This is a working overview of c-Met, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-30 and is reviewed periodically as new material appears.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
=== Purpose === The purpose of studying the proteome is to better understand the activity of proteins at the single-cell level. Since proteins are responsible for determining how the cell acts, understanding the proteome of single cells gives the best understanding of how a cell operates, and how gene expression changes in a cell due to different environmental stimuli. Although transcriptomics has the same purpose as proteomics it is not as accurate at determining gene expression in cells as it does not take into account post-transcriptional regulation (not all messenger RNA transcripts are actually translated into proteins). Transcriptomics is still important, of course, as studying the difference between RNA levels and protein levels can give insight regarding which genes are post-transcriptionally regulated.
In 1913, the first electric refrigerators for home and domestic use were invented and produced by Frederick William Wolf Jr. of Fort Wayne, Indiana, with models consisting of a unit that was mounted on top of an ice box. His first device, produced over the next few years in several hundred units, was called DOMELRE. In 1914, engineer Nathaniel B. Wales of Detroit, Michigan, introduced an idea for a practical electric refrigeration unit, which later became the basis for the Kelvinator. A self-contained refrigerator, with a compressor on the bottom of the cabinet was invented by Alfred Mellowes in 1916. Mellowes produced this refrigerator commercially but was bought out by William C. Durant in 1918, who started the Frigidaire company to mass-produce refrigerators. In 1918, Kelvinator company introduced the first refrigerator with any type of automatic control. The absorption refrigerator was invented by Baltzar von Platen and Carl Munters from Sweden in 1922, while they were still students at the Royal Institute of Technology in Stockholm. It became a worldwide success and was commercialized by Electrolux. Other pioneers included Charles Tellier, David Boyle, and Raoul Pictet. Carl von Linde was the first to patent and make a practical and compact refrigerator. These home units usually required the installation of the mechanical parts, motor and compressor, in the basement or an adjacent room while the cold box was located in the kitchen.
Following extended discussions with Richwood Pharmaceuticals regarding the resolution of a large number of issues related to the company's numerous violations of FDA regulations, the FDA formally approved the first Obetrol labeling/sNDA revisions in 1996, including a name change to Adderall and a restoration of its status as an approved drug product. In 1997 Richwood Pharmaceuticals was acquired by Shire Pharmaceuticals in a $186 million transaction. Richwood Pharmaceuticals, which later merged with Shire, introduced the Adderall brand in 1996 as an instant-release tablet. In 2006, Shire agreed to sell rights to the Adderall name for the instant-release form of the medication to Duramed Pharmaceuticals. DuraMed Pharmaceuticals was acquired by Teva Pharmaceuticals in 2008 during their acquisition of Barr Pharmaceuticals, including Barr's Duramed division. The first generic version of Adderall IR was introduced to the market in 2002. Later on, Barr and Shire reached a settlement agreement permitting Barr to offer a generic form of the extended-release drug beginning in April 2009.
== History == ARUP was founded by John Matsen and Carl Kjeldsberg, based on Lloyd Martin's vision of an independent, not-for-profit laboratory owned by the Department of Pathology. ARUP's facilities operate with a high degree of automation. Their 65 laboratories include sorters, automated thawing and mixing, and house a two-story automated lab specimen freezer. The freezer can store 2.3 million specimens and retrieve a specimen in 2.5 minutes. In 2003, ARUP partnered with the Utah Department of Health to create a pilot program for expanding newborn screening in Utah to include an additional 30 metabolic markers. A year later, this program became the standard for the mandatory screening of all newborns in the state of Utah.
However, if the analyte being tested has a low mass value then it can produce a similar looking spectra to that of a MALDI spectra. ME-SIMS has been so effective that it has been able to detect low mass chemicals at sub cellular levels that was not possible prior to the development of the ME-SIMS technique. The second technique being used is called sample metallization (Meta-SIMS) - This is the process of gold or silver addition to the sample. This forms a layer of gold or silver around the sample and it is normally no more than 1-3 nm thick. Using this technique has resulted in an increase of sensitivity for larger mass samples. The addition of the metallic layer also allows for the conversion of insulating samples to conducting samples, thus charge compensation within SIMS experiments is no longer required. Subcellular (50 nm) resolution is enabled by NanoSIMS allowing for absolute quantitative analysis at the organelle level.
Sources: en.wikipedia.org
=== Analogues === A notable analogue of SDMA is 4T-MMDA-2 (2-methoxy-4T-MDA), which was described by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved). Other analogues of SDMA include SDA, MDMA, 5-MAPB, and 6-MAPBT, among others.
== Histopathology == The most common finding of a histopathology is an acidophil adenoma of the pituitary gland, this occurs in most cases. In rare occasions no tumour will be found, however, a proliferation of acidophilic cells will be discovered. Other findings may include adenomatous hyperplasia of the thyroid and parathyroid glands, multinodular hyperplasia of the adrenal cortices, multifocal or disseminated nodular hyperplasia of the pancreas with ductal fibrosis, lymphocytic-plasmacytic infiltration, hyalinisation of the islets, and amyloid deposition.
A brand extension, combining the TGI Fridays concept with the atmosphere of a sports bar, called "Fridays Front Row Sports Grill", is found at two Major League Baseball stadiums which each overlook the playing field: Chase Field in Phoenix, Arizona and Miller Park in Milwaukee. There was also a Friday's Front Row Grill for a few seasons at Globe Life Park, then the Texas Rangers home field.
A 2023 review in Frontiers in Allergy identified genetic loci associated with allergic disease, clustering into four functional categories: regulation of inflammatory responses (e.g., IL-4, IL-13), maintenance of epithelial barrier integrity (e.g., FLG), immune cell signaling (e.g., STAT6), and susceptibility to allergic sensitization (e.g., ORMDL3). Some loci, such as PRDM2 and POU2AF1, showed pleiotropic effects linking allergic and autoimmune conditions, suggesting shared inflammatory pathways across epithelial tissues. Within atopic airway disease specifically, the same review noted that IL-13—produced mainly by activated TH2 cells—is a key driver of eosinophilic airway inflammation and remodeling, acting partly through pathways independent of IgE and eosinophils.
Radon has no stable isotopes and no standard atomic weight. Thirty-nine radioactive isotopes have been characterized, with mass numbers ranging from 193 to 231. Six of them, from 217 to 222 inclusive, occur naturally. The most stable isotope is 222Rn (half-life 3.82 days), which is a decay product of 226Ra, the latter being itself a decay product of 238U. A trace amount of the (highly unstable) isotope 218Rn (half-life about 35 milliseconds) is also among the daughters of 222Rn. The isotope 216Rn would be produced by the double beta decay of natural 216Po; while energetically possible, this process has however never been seen. Three other radon isotopes have a half-life of over an hour: 211Rn (about 15 hours), 210Rn (2.4 hours) and 224Rn (about 1.8 hours). However, none of these three occur naturally. 220Rn, also called thoron, is a natural decay product of the most stable thorium isotope (232Th). It has a half-life of 55.6 seconds and also emits alpha radiation. Similarly, 219Rn is derived from the most stable isotope of actinium (227Ac)—named "actinon"—and is an alpha emitter with a half-life of 3.96 seconds.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.